[1] |
LIU Y N, ZHANG Y F, XU Q, et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020:a national surveillance study[J]. Lancet Microbe, 2023, 4(5):e330-e339.
|
[2] |
程子嘉, 陈诚, 李新科. 血清炎性因子联合微生物检验对耐药肺炎克雷伯菌脓毒症诊断和预后分析[J]. 河北医药, 2022, 44(24):3824-3826.
|
[3] |
刘心伟, 李登州, 胡玥, 等. 2020—2022年河南省某医院高毒力耐碳青霉烯类肺炎克雷伯菌分子流行病学特征研究[J]. 中华预防医学杂志, 2023, 57(8):1222-1230.
|
[4] |
World Health Organization. Antimicrobial resistance,hypervirulent Klebsiella pneumoniae-global situation[EB/OL].(2024-07-31)[2024-10-12]. https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON527.
|
[5] |
中华预防医学会医院感染控制分会, 中华医学会感染病学分会, 中国医院协会医院感染管理专业委员会, 等. 中国碳青霉烯耐药革兰阴性杆菌(CRO)感染预防与控制技术指引[J]. 中华医院感染学杂志, 2019, 29(13):2075-2080.
|
[6] |
WEINSTEIN M P, LEWIS J S 2nd. The clinical and laboratory standards institute subcommittee on antimicrobial susceptibility testing:background,organization,functions,and processes[J]. J Clin Microbiol, 2020, 58(3):e01864.
|
[7] |
GU D, DONG N, ZHENG Z, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital:a molecular epidemiological study[J]. Lancet Infect Dis, 2018, 18(1):37-46.
|
[8] |
DENISSEN J, REYNEKE B, WASO-REYNEKE M, et al. Prevalence of ESKAPE pathogens in the environment:antibiotic resistance status,community-acquired infection and risk to human health[J]. Int J Hyg Environ Health, 2022,244:114006.
|
[9] |
乔艳, 孙红, 李江艳, 等. 某教学医院耐碳青霉烯类高毒力肺炎克雷伯菌临床及分子特征[J]. 中国感染控制杂志, 2022, 21(12):1185-1192.
|
[10] |
LIU C, GUO J. Hypervirulent Klebsiella pneumoniae(hypermucoviscous and aerobactin positive)infection over 6 years in the elderly in China:antimicrobial resistance patterns,molecular epidemiology and risk factor[J]. Ann Clin Microbiol Antimicrob, 2019, 18(1):4.
|
[11] |
黄韵, 李从荣, 汪倩钰, 等. 耐碳青霉烯高毒力肺炎克雷伯菌的耐药性及临床、分子特征分析[J]. 山东医药, 2021, 61(29):43-46.
|
[12] |
祝俊英, 魏清, 沈震, 等. 高毒力肺炎克雷伯菌中KPC-2型碳青霉烯酶对细菌毒力的影响[J]. 中国感染与化疗杂志, 2021, 21(6):697-702.
DOI
|
[13] |
TIAN D, LIU X, CHEN W, et al. Prevalence of hypervirulent and carbapenem-resistant Klebsiella pneumoniae under divergent evolutionary patterns[J]. Emerg Microbes Infect, 2022, 11(1):1936-1949.
|
[14] |
杜芳玲, 梅艳芳, 魏丹丹, 等. CRKP血流感染危险因素和耐药及毒力特征[J]. 中华医院感染学杂志, 2021, 31(22):3361-3365.
|
[15] |
YANG Y, LIU J H, HU X X, et al. Clinical and microbiological characteristics of hypervirulent Klebsiella pneumoniae(hvKp)in a hospital from north China[J]. J Infect Dev Ctries, 2020, 14(6):606-613.
|
[16] |
丁兴伟, 韩逸青, 王晖, 等. 2017至2019年上海和湖南两医院耐碳青霉烯类肺炎克雷伯菌的流行病学研究[J]. 河北医药, 2023, 45(9):1418-1423.
|
[17] |
XIE M, YE L, CHEN K, et al. Clinical use of tigecycline may contribute to the widespread dissemination of carbapenem-resistant hypervirulent Klebsiella pneumoniae strains[J]. Emerg Microbes Infect, 2024, 13(1):2306957.
|
[18] |
王明贵. 广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制:中国专家共识[J]. 中国感染与化疗杂志, 2017, 17(1):82-93.
|
[19] |
RÖDEL J, PFEIFER Y, FISCHER M A, et al. Screening of Klebsiella pneumoniae isolates for carbapenemase and hypervirulence-associated genes by combining the eazyplex® superbug CRE and hvKpassays[J]. Antibiotics(Basel), 2023, 12(6):959.
|
[20] |
MAI D, WU A, LI R, et al. Identification of hypervirulent Klebsiella pneumoniae based on biomarkers and Galleria mellonella infection model[J]. BMC Microbiol, 2023, 23(1):369.
|
[21] |
RUSSO A, FUSCO P, MORRONE H L, et al. New advances in management and treatment of multidrug-resistant Klebsiella pneumoniae[J]. Expert Rev Anti Infect Ther, 2023, 21(1):41-55.
|